Prognostic factors and outcomes in patients with leptomeningeal melanomatosis
- PMID: 18708343
- PMCID: PMC2718998
- DOI: 10.1215/15228517-2008-062
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis
Abstract
The purpose of this study was to describe a cohort of patients with leptomeningeal melanomatosis (LM) and to determine prognostic factors for outcomes in these patients. The primary hypothesis was that more extensive burden of CNS metastasis at the time of diagnosis of LM (as evidenced by imaging of the CNS parenchyma and meninges and cerebrospinal fluid [CSF] cytology status [positive versus negative]) correlates with poorer outcomes. The records of all patients with LM treated at M. D. Anderson Cancer Center between 1944 and 2002 were reviewed. Information on clinical course and outcomes was gathered. Univariate and multivariate analyses were performed on 110 patients using Cox proportional hazards regression analysis to examine the effects of possible predictive factors on survival. The overall median survival from LM diagnosis was 10 weeks, with a 95% confidence interval (CI) of 8-14 weeks. Eighty-six (78.2%) patients had cutaneous primary lesions, and 23 (20.9%) had melanoma of unknown primary site. The primary hypothesis was not proven. Neither the presence of parenchymal CNS metastases, nor greater imaging evidence of LM, nor positive CSF cytology at diagnosis correlated with survival outcomes. Univariate analyses revealed possible predictors of longer survival, including the presence of supratentorial or spinal LM on imaging at diagnosis versus its absence and any treatment of LM, whereas elevated serum lactate dehydrogenase at the time of LM diagnosis predicted shorter survival. Multivariate analysis revealed that a history of a primary melanoma lesion originating on the trunk predicted shorter survival after LM diagnosis (hazard ratio [HR] = 2.0, 95% CI = 1.0-3.8, p = 0.035), and treatment with intrathecal chemotherapy predicted longer survival (HR = 0.5, 95% CI = 0.4-0.8, p = 0.0036). The positive result with respect to treatment is unreliable due to the inability to remove treatment selection bias from the analysis. This retrospective analysis confirmed the dismal prognosis associated with LM. The amount of CNS tumor burden at the time of diagnosis of LM did not inversely correlate with survival outcomes, contrary to our hypothesis.
Figures
Similar articles
-
Leptomeningeal metastasis: Clinical experience of 519 cases.Eur J Cancer. 2016 Mar;56:107-114. doi: 10.1016/j.ejca.2015.12.021. Epub 2016 Feb 1. Eur J Cancer. 2016. PMID: 26841095
-
Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors.Eur J Cancer. 2025 May 2;220:115377. doi: 10.1016/j.ejca.2025.115377. Epub 2025 Mar 28. Eur J Cancer. 2025. PMID: 40184847
-
Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.Radiat Oncol. 2019 Sep 14;14(1):168. doi: 10.1186/s13014-019-1376-z. Radiat Oncol. 2019. PMID: 31521171 Free PMC article.
-
Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.Eur J Cancer. 2021 Jun;150:23-30. doi: 10.1016/j.ejca.2021.03.037. Epub 2021 Apr 18. Eur J Cancer. 2021. PMID: 33882375
-
[Advances in Diagnosis and Treatment of Leptomeningeal Metastasis of Lung Cancer].Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):517-523. doi: 10.3779/j.issn.1009-3419.2022.102.25. Zhongguo Fei Ai Za Zhi. 2022. PMID: 35899451 Free PMC article. Review. Chinese.
Cited by
-
Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report.BMC Cancer. 2015 May 13;15:400. doi: 10.1186/s12885-015-1391-x. BMC Cancer. 2015. PMID: 25962795 Free PMC article.
-
Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.Am J Clin Dermatol. 2018 Aug;19(4):529-541. doi: 10.1007/s40257-018-0346-9. Am J Clin Dermatol. 2018. PMID: 29417399 Free PMC article. Review.
-
Cerebrospinal Fluid Profiles and Their Changes after Intraventricular Chemotherapy as Prognostic or Predictive Markers for Patients with Leptomeningeal Carcinomatosis.J Korean Neurosurg Soc. 2021 Jul;64(4):631-643. doi: 10.3340/jkns.2020.0300. Epub 2021 Jun 29. J Korean Neurosurg Soc. 2021. PMID: 34185980 Free PMC article.
-
Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe.J Neurooncol. 2017 Jun;133(2):419-427. doi: 10.1007/s11060-017-2452-6. Epub 2017 Apr 28. J Neurooncol. 2017. PMID: 28455788
-
Focal leptomeningeal vascular anomalies on brain MRI: A mimic of leptomeningeal metastatic disease.Neurooncol Pract. 2024 Jun 7;11(6):772-778. doi: 10.1093/nop/npae050. eCollection 2024 Dec. Neurooncol Pract. 2024. PMID: 39554785 Free PMC article.
References
-
- Groves MD. Leptomeningeal carcinomatosis: diagnosis and management. In: Sawaya R, editor. Intracranial Metastases: Current Management Strategies. Malden, MA: BlackwellFutura; 2004. pp. 309–330.
-
- Balm M, Hammack J. Leptomeningeal carcinomatosis: presenting features and prognostic factors. Arch Neurol. 1996;53:626–632. - PubMed
-
- Yap HY, Yap BS, Rasmussen S, et al. Treatment for meningeal carcinomatosis in breast cancer. Cancer. 1982;15:219–222. - PubMed
-
- Rosen ST, Aisner J, Makuch RW, et al. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review for the National Cancer Institute experience. Medicine (Baltimore) 1982;61:45–53. - PubMed
-
- Amer MH, Al-Sarraf M, Baker LH, et al. Malignant melanoma and central nervous system metastasis: incidence, diagnosis, treatment, and survival. Cancer. 1978;42:660–668. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical